Nature Communications,
Journal Year:
2023,
Volume and Issue:
14(1)
Published: Nov. 9, 2023
The
blood
proteome
holds
great
promise
for
precision
medicine
but
poses
substantial
challenges
due
to
the
low
abundance
of
most
plasma
proteins
and
vast
dynamic
range
proteome.
Here
we
address
these
with
NUcleic
acid
Linked
Immuno-Sandwich
Assay
(NULISA™),
which
improves
sensitivity
traditional
proximity
ligation
assays
by
~10,000-fold
attomolar
level,
suppressing
assay
background
via
a
dual
capture
release
mechanism
built
into
oligonucleotide-conjugated
antibodies.
Highly
multiplexed
quantification
both
low-
high-abundance
spanning
wide
is
achieved
attenuating
signals
from
abundant
targets
unconjugated
antibodies
next-generation
sequencing
barcoded
reporter
DNA.
A
200-plex
NULISA
containing
124
cytokines
chemokines
other
demonstrates
superior
extension
in
detecting
biologically
important
low-abundance
biomarkers
patients
autoimmune
diseases
COVID-19.
Fully
automated
makes
broad
in-depth
proteomic
analysis
easily
accessible
research
diagnostic
applications.
Science,
Journal Year:
2020,
Volume and Issue:
369(6499)
Published: April 28, 2020
A
real-time
trial
of
a
cancer
blood
test
Cancers
diagnosed
early
are
often
more
responsive
to
treatment.
Blood
tests
that
detect
molecular
markers
have
successfully
identified
individuals
already
known
the
disease.
Lennon
et
al.
conducted
an
exploratory
study
closely
reflects
way
in
which
such
would
be
used
future.
They
evaluated
feasibility
and
safety
incorporating
multicancer
into
routine
clinical
care
10,000
women
with
no
history
cancer.
Over
12-month
period,
detected
26
cancers
different
types.
combination
positron
emission
tomography–computed
tomography
(PET-CT)
imaging
led
surgical
removal
nine
these
cancers.
Use
did
not
result
large
number
futile
follow-up
procedures.
Science
,
this
issue
p.
eabb9601
Cancer Cell,
Journal Year:
2022,
Volume and Issue:
40(12), P. 1537 - 1549.e12
Published: Nov. 17, 2022
In
the
Circulating
Cell-free
Genome
Atlas
(NCT02889978)
substudy
1,
we
evaluate
several
approaches
for
a
circulating
cell-free
DNA
(cfDNA)-based
multi-cancer
early
detection
(MCED)
test
by
defining
clinical
limit
of
(LOD)
based
on
tumor
allele
fraction
(cTAF),
enabling
performance
comparisons.
Among
10
machine-learning
classifiers
trained
same
samples
and
independently
validated,
when
evaluated
at
98%
specificity,
those
using
whole-genome
(WG)
methylation,
single
nucleotide
variants
with
paired
white
blood
cell
background
removal,
combined
scores
from
in
this
study
show
highest
cancer
signal
sensitivities.
Compared
stage
type,
cTAF
is
more
significant
predictor
classifier
may
closely
reflect
biology.
Clinical
LODs
mirror
relative
sensitivities
all
approaches.
The
WG
methylation
feature
best
predicts
origin.
most
promising
technology
MCED
informs
development
targeted
test.
Signal Transduction and Targeted Therapy,
Journal Year:
2024,
Volume and Issue:
9(1)
Published: May 20, 2024
Abstract
Tumor
biomarkers,
the
substances
which
are
produced
by
tumors
or
body’s
responses
to
during
tumorigenesis
and
progression,
have
been
demonstrated
possess
critical
encouraging
value
in
screening
early
diagnosis,
prognosis
prediction,
recurrence
detection,
therapeutic
efficacy
monitoring
of
cancers.
Over
past
decades,
continuous
progress
has
made
exploring
discovering
novel,
sensitive,
specific,
accurate
tumor
significantly
promoted
personalized
medicine
improved
outcomes
cancer
patients,
especially
advances
molecular
biology
technologies
developed
for
detection
biomarkers.
Herein,
we
summarize
discovery
development
including
history
conventional
innovative
used
biomarker
classification
biomarkers
based
on
tissue
origins,
application
clinical
management.
In
particular,
highlight
recent
advancements
biomarker-based
anticancer-targeted
therapies
emerging
as
breakthroughs
promising
strategies.
We
also
discuss
limitations
challenges
that
need
be
addressed
provide
insights
perspectives
turn
into
opportunities
this
field.
Collectively,
multiple
emphasized
review
may
guidance
precision
medicine,
broaden
horizons
future
research
directions,
expedite
patients
according
their
rather
than
organs
origin.
Cell Death and Disease,
Journal Year:
2020,
Volume and Issue:
11(7)
Published: July 27, 2020
Abstract
Extracellular
vesicles
(EVs)
and
particles
(EPs)
have
recently
emerged
as
active
carriers
of
molecular
biomarkers
mediators
intercellular
communication.
While
most
investigations
focused
exclusively
on
the
protein,
lipid
RNA
constituents
these
extracellular
entities,
EV/EP
DNA
remains
poorly
understood,
despite
being
found
in
association
with
virtually
all
populations.
The
functional
potential
has
been
proposed
a
number
pathological
states,
including
malignancies
autoimmune
diseases.
Moreover,
effectiveness
cell-free
biomarker
choice
emerging
liquid
biopsy
applications
highlights
role
that
may
play
novel
disease
biomarker.
In
this
review,
we
provide
comprehensive
overview
studies
conducted
to
date,
particular
focus
roles
mediator
various
pathologic
states.
We
also
review
what
is
currently
known
about
origins,
structure,
localisation
distribution
DNA,
highlighting
current
controversies
well
opportunities
for
future
investigation.